[Comprehensive view of hepatitis and the other reactions secondary to antituberculosis chemotherapy]

[Article in French]

[Article in French]

D J Girling. Bull Int Union Tuberc. 1980 Mar-Jun.

. 1980 Mar-Jun;55(1-2):9-13.

No abstract available

Similar articles

Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Vu D, Macdonald L. Vu D, et al. CMAJ. 2001 Oct 2;165(7):942-3, 946-7. CMAJ. 2001. PMID: 11599338 Review. English, French. No abstract available.
Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ. Lee BH, et al. Chest. 2005 Apr;127(4):1304-11. doi: 10.1378/chest.127.4.1304. Chest. 2005. PMID: 15821209
Antituberculosis drugs and hepatotoxicity.
Sharma SK. Sharma SK. Infect Genet Evol. 2004 Jun;4(2):167-70. doi: 10.1016/j.meegid.2003.01.001. Infect Genet Evol. 2004. PMID: 15157635 No abstract available.
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2001 Apr 20;50(15):289-91. MMWR Morb Mortal Wkly Rep. 2001. PMID: 11330495
Antituberculosis drugs and hepatotoxicity.
Yew WW, Leung CC. Yew WW, et al. Respirology. 2006 Nov;11(6):699-707. doi: 10.1111/j.1440-1843.2006.00941.x. Respirology. 2006. PMID: 17052297 Review.